The agreement covers the development and marketing of the drug following a single clinical trial due to begin in 2020. If successful, this trial could lead directly to the drug's approval. LYON, ...

Beyond Batten Disease Foundation (BBDF) is the world's largest nonprofit organization dedicated to funding research for a treatment and cure for juvenile (CLN3) Batten disease. Since its inception in ...

AUSTIN (KXAN) — As teenagers, the Benson siblings have been through experiences many kids their age never face. Christiane, 15, and Garland, 13, go skiing, play sports and run around the backyard with ...

Let me tell you about a mission I’m on — one that’s very personal, but could have far-reaching implications. To accomplish that mission, I just need a little help from 100,000 friends and strangers.

NEW YORK, NY -- The New York Stem Cell Foundation (NYSCF) and Beyond Batten Disease Foundation (BBDF) have partnered to develop stem cell resources to investigate and explore new treatments and ...

AUSTIN, Texas, March 2, 2021 /PRNewswire/ -- Beyond Batten Disease Foundation (BBDF) is pleased to announce an agreement with Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson ...

Theranexus SA (FR:ALTHX) has released an update. Theranexus, in collaboration with the Beyond Batten Disease Foundation, reports positive 18-month results from its phase 1/2 study of Batten-1, ...

Lyon, 9 September 2021 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and Beyond Batten Disease Foundation (BBDF), announce receipt of Investigational ...

Omar Villafranca is a CBS News correspondent based in Dallas. He joined CBS News in 2014 as a correspondent for Newspath. Before CBS, Villafranca worked at KXAS-TV Dallas-Fort Worth, at KOTV-TV the ...

LYON, FRANCE and AUSTIN, TX / ACCESS Newswire / May 13, 2025 / Theranexus, a biopharmaceutical company developing drug candidates for rare neurological diseases, and the Beyond Batten Disease ...

Beyond Batten Disease Foundation (BBDF) funded research aimed at identifying and validating BBDF-101, a proprietary combination of drugs relying on the synergistic effect of two active ingredients, ...